MedKoo Cat#: 317575 | Name: Cycrimine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cycrimine (trade name Pagitane) is a central anticholinergic drug designed to reduce the levels of acetylcholine in the treatment of Parkinson's disease. Its mechanism of action is to bind to the muscarinic acetylcholine receptor M1.

Chemical Structure

Cycrimine
Cycrimine
CAS#77-39-4 (free base)

Theoretical Analysis

MedKoo Cat#: 317575

Name: Cycrimine

CAS#: 77-39-4 (free base)

Chemical Formula: C19H29NO

Exact Mass: 287.2249

Molecular Weight: 287.44

Elemental Analysis: C, 79.39; H, 10.17; N, 4.87; O, 5.57

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Cycrimine; Pagitane; Cicrimina; Cycriminum; (+)-cycrimine; Cicrimina
IUPAC/Chemical Name
1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol
InChi Key
SWRUZBWLEWHWRI-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H29NO/c21-19(18-11-5-6-12-18,17-9-3-1-4-10-17)13-16-20-14-7-2-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2
SMILES Code
C1CCN(CC1)CCC(C2CCCC2)(C3=CC=CC=C3)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 287.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Winger RH, Liedl KR, Sotriffer CA, Gamper AM, Rode BM, Kroemer RT, Varga JM. Prediction of IgE(Lb4)-ligand complex structures by automated docking. J Mol Recognit. 1996 May-Jun;9(3):239-46. PubMed PMID: 8938597. 2: Sotriffer CA, Liedl KR, Winger RH, Gamper AM, Kroemer RT, Linthicum DS, Rode BM, Varga JM. Heteroligation of a mouse monoclonal IgE antibody (La2) with small molecules, analysed by computer-aided automated docking. Mol Immunol. 1996 Feb;33(2):129-44. PubMed PMID: 8649435. 3: Owen JA, Sribney M, Lawson JS, Delva N, Letemendia FJ. Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42. PubMed PMID: 2573609. 4: Occelli E, Fontanella L, Testa E. [Bicyclic analogs of piperazine. XII. (1) - Synthesis of 3,8-diazabicyclo/3,2,1/octanes as potential antiparkinson agents]. Farmaco Sci. 1977 Apr;32(4):237-47. Italian. PubMed PMID: 862878. 5: Vedasiromoni JR, Ganguly DK. Cycrimine on rat diaphragm. Arch Int Pharmacodyn Ther. 1976 Jan;219(1):64-9. PubMed PMID: 1267542. 6: RENZI AA, MILCH LJ. Effectiveness of procyclidine hydrochloride (kemadrin) and cycrimine hydrochloride (pagitane) in the prevention of airsickness. J Aviat Med. 1958 Aug;29(8):587-9. PubMed PMID: 13575361. 7: KAFER JP, POCH GF. [Cycrimine, a new drug in the treatment of Parkinson's disease & Parkinsonism]. Prensa Med Argent. 1957 Apr 5;44(14):1071-5. Spanish. PubMed PMID: 13477721. 8: SIGWALD J, PAYOT J. [Symptomatic therapeutic effect of cycrimine HCl in parkinsonian syndromes]. Presse Med. 1955 Mar 12;63(19):375-6. French. PubMed PMID: 14371520. 9: NEW AND nonofficial remedies: cycrimine hydrochloride. J Am Med Assoc. 1955 Feb 5;157(6):510-1. PubMed PMID: 13221464.